(Q37981730)

26 August 2017

title

The use of methotrexate in dermatology: a review (English)

1 reference

26 August 2017

1 reference

Sarah Shen

1

1 reference

26 August 2017

Tim O'Brien

2

1 reference

26 August 2017

Lei Mee Yap

3

1 reference

26 August 2017

H Miles Prince

4

1 reference

26 August 2017

Christopher J McCormack

5

1 reference

26 August 2017

publication date

29 December 2011

1 reference

Australasian Journal of Dermatology

26 August 2017

published in

1 reference

26 August 2017

volume

53

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

1-18

1 reference

Methotrexate for psoriasis. A new therapeutic schedule

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The clinical pharmacology of methotrexate.new applications of an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate--how does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Adenosine: an endogenous regulator of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate and histologic hepatic abnormalities: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Epstein-Barr virus-associated B-cell type non-Hodgkin's lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The effects of methotrexate on pregnancy, fertility and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Antirheumatic drugs in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Oral effects of low-dose methotrexate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Erosion of psoriatic plaques: an early sign of methotrexate toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Cutaneous ulceration caused by methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Effect of drugs on homocysteine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Toward a better understanding of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Anaphylactoid reactions to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate exposure prior to and during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Folate supplementation during methotrexate therapy for patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Resolution of pityriasis rubra pilaris-induced cicatricial ectropion with systemic low-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Mucha-Habermann's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Septic, CD-30 positive febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate-responsive chronic idiopathic urticaria: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Immunosuppressants in the treatment of pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Use of methotrexate to treat pemphigus foliaceus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Low-dose methotrexate treatment in elderly patients with bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

A retrospective analysis of patients with bullous pemphigoid treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Pediatric morphea (localized scleroderma): review of 136 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Low-dose methotrexate in the treatment of widespread morphea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Treatment of dermatomyositis with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Amyopathic dermatomyositis: retrospective review of 37 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate for the treatment of discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Low-dose methotrexate controls a severe form of polyarteritis nodosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Cutaneous sarcoidosis treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Successful treatment of disseminated granuloma annulare with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Systemic combination treatment for psoriasis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate-betamethasone weekly oral pulse in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

The efficacy of methotrexate in psoriasis--a review of 40 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Oral retinoids--efficacy and toxicity in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Recognition and treatment of psoriasis. Special considerations in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Methotrexate dosage in patients aged over 50 with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

21 January 2018

Treatment of scleroderma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Cutaneous and systemic manifestations of drug-induced vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Cutaneous sarcoidosis therapy updated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

How I treat mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-0960.2011.00839.X

10.1111/J.1440-0960.2011.00839.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference